Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins

Elisabeth K. Nyakatura, Samantha E. Zak, Anna Z. Wec, Daniel Hofmann, Sergey Shulenin, R. R. Bakken, M. Javad Aman, Kartik Chandran, John M. Dye, Jonathan R. Lai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.

Original languageEnglish (US)
Pages (from-to)6201-6211
Number of pages11
JournalJournal of Biological Chemistry
Volume293
Issue number16
DOIs
StatePublished - Jan 1 2018

Fingerprint

Ebolavirus
Bispecific Antibodies
Viruses
Glycoproteins
Marburgvirus
Virus Diseases
Disease Outbreaks
Filoviridae
Cross Protection
Western Africa
Epitopes
Pathogens
Mortality
Antibodies
Infection

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. / Nyakatura, Elisabeth K.; Zak, Samantha E.; Wec, Anna Z.; Hofmann, Daniel; Shulenin, Sergey; Bakken, R. R.; Javad Aman, M.; Chandran, Kartik; Dye, John M.; Lai, Jonathan R.

In: Journal of Biological Chemistry, Vol. 293, No. 16, 01.01.2018, p. 6201-6211.

Research output: Contribution to journalArticle

Nyakatura, Elisabeth K. ; Zak, Samantha E. ; Wec, Anna Z. ; Hofmann, Daniel ; Shulenin, Sergey ; Bakken, R. R. ; Javad Aman, M. ; Chandran, Kartik ; Dye, John M. ; Lai, Jonathan R. / Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. In: Journal of Biological Chemistry. 2018 ; Vol. 293, No. 16. pp. 6201-6211.
@article{51dcab50dabf49e4a6d6d3173f0ffc9b,
title = "Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins",
abstract = "Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90{\%}). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.",
author = "Nyakatura, {Elisabeth K.} and Zak, {Samantha E.} and Wec, {Anna Z.} and Daniel Hofmann and Sergey Shulenin and Bakken, {R. R.} and {Javad Aman}, M. and Kartik Chandran and Dye, {John M.} and Lai, {Jonathan R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1074/jbc.RA117.001627",
language = "English (US)",
volume = "293",
pages = "6201--6211",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "16",

}

TY - JOUR

T1 - Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins

AU - Nyakatura, Elisabeth K.

AU - Zak, Samantha E.

AU - Wec, Anna Z.

AU - Hofmann, Daniel

AU - Shulenin, Sergey

AU - Bakken, R. R.

AU - Javad Aman, M.

AU - Chandran, Kartik

AU - Dye, John M.

AU - Lai, Jonathan R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.

AB - Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30 -90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered bi- and trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries.

UR - http://www.scopus.com/inward/record.url?scp=85045844693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045844693&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA117.001627

DO - 10.1074/jbc.RA117.001627

M3 - Article

C2 - 29500195

AN - SCOPUS:85045844693

VL - 293

SP - 6201

EP - 6211

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 16

ER -